METABOLISM OF OPIOIDS IS ALTERED IN LIVER MICROSOMES OF SICKLE CELL TRANSGENIC MICE
|
|
- Francis Barber
- 6 years ago
- Views:
Transcription
1 /04/ $20.00 DRUG METABOLISM AND DISPOSITION Vol. 32, No. 1 Copyright 2004 by The American Society for Pharmacology and Experimental Therapeutics 1103/ DMD 32:98 104, 2004 Printed in U.S.A. METABOLISM OF OPIOIDS IS ALTERED IN LIVER MICROSOMES OF SICKLE CELL TRANSGENIC MICE Swati Nagar, Rory P. Remmel, Robert P. Hebbel, and Cheryl L. Zimmerman Departments of Pharmaceutics (S.N., C.L.Z.), Medicinal Chemistry (R.P.R.), and Medicine (R.P.H.), University of Minnesota, Minneapolis, Minnesota (Received March 3, 2003; accepted September 15, 2003) This article is available online at ABSTRACT: The genetic basis of sickle cell anemia (SCA 1 ), a hemoglobin disorder, has been understood since 1949 (Pauling et al., 1949); red blood cells (RBCs) assume a sickle shape when deoxygenated due to a point mutation in the beta-globin gene of the hemoglobin molecule. In the United States alone, around 1000 babies are born every year with SCA, and it is estimated that 1 in every 600 African Americans is homozygous for the mutation (Steinberg, 1999). Sickling of RBCs affects almost all organs of the body, including the heart, lung, kidneys, and liver. Among the various complications of SCA, acute and chronic pain syndromes cause the highest number of hospital visits. The intense pain is commonly managed with opioid analgesics This project was funded partially by National Institutes of Health Grant HL55552 to R.P.H., and the William and Mildred Peters Endowment, Department of Pharmaceutics, University of Minnesota. This work was submitted by S.N. in partial completion of the requirements for the Ph.D. in Pharmaceutics at the University of Minnesota. 1 Abbreviations used are: SCA, sickle cell anemia; RBC, red blood cell; UGT, uridine glucuronosyltransferase, human; ugt, uridine glucuronosyltransferase, rodent; P450, cytochrome P450; SC, sickle cell transgenic mice; SCKO, sickle cell-knockout mice; NB, norbuprenorphine; M3G, morphine-3-glucuronide; UD- PGA, uridine diphosphoglucuronic acid; G6P, glucose-6-phosphate; HPLC, highpressure liquid chromatography; ACN, acetonitrile; BG, buprenorphine glucuronide; E3G, estradiol-3-glucuronide; E17G, estradiol-17-glucuronide; EE2, ethynylestradiol; Cl int, intrinsic clearance of unbound drug. Address correspondence to: Dr. Cheryl L. Zimmerman, College of Pharmacy, University of Minnesota, 308 Harvard St. S.E, Minneapolis, MN zimme005@umn.edu 98 Pain in sickle cell anemia (SCA) is clinically managed with opioid analgesics. There are reports that SCA patients tolerate high doses of these drugs without adequate pain relief. The current study investigated the in vitro hepatic metabolism of opioids in mouse models of sickle cell anemia, with the hypothesis that higher dose requirements in SCA could be explained by an increased metabolism rate of opioids. Various rodent cytochrome P450 substrates, i.e., buprenorphine and codeine, and rodent uridine glucuronosyltransferase substrates, i.e., morphine, buprenorphine, and estradiol, were studied. The three groups used were: 1) control C57BL mice, 2) mice with the human -globin and sickle -globin transgenes (SC), and 3) mice with the human -globin and sickle -globin transgenes, and homozygous for the murine -globin and heterozygous for the major -gene knockout (SCKO). In vitro hepatic microsomal incubations were carried out for each substrate, and data were fit to the Michaelis-Menten equation. Morphine formation had a higher V max in SCKO microsomes ( nmol/min mg; estimate S.E.) than controls ( ). Morphine-3- glucuronide formation had V max estimates of , , and nmol/min mg in control, SC, and SCKO microsomes, respectively. The control V max for estradiol-3-glucuronide formation was 2-fold greater than in SCKO microsomes. The control V max for estradiol 17-glucuronide formation was 3.4- and 2.2- fold greater than in SC and SCKO microsomes. Thus, in vitro metabolism of opioids is altered in SCA mouse models, which may lead to altered clearances of these drugs. including morphine, buprenorphine, and nalbuphine (Embury et al., 1994). There have been various clinical reports that sickle pain is not adequately managed by typical doses of opioids, and SCA patients can tolerate very high doses of analgesics without alleviation of their symptoms (Dampier et al., 1995; Beyer, 2000; Yaster et al., 2000). Studies have been limited due to the complexity of study designs involving persons with SCA, many of whom are pediatric patients. Studies in SCA patients have indicated that one possible reason for higher dose requirement is an alteration in drug pharmacokinetics. The elimination half-life of codeine in sickle cell patients was found to be significantly shorter than in control subjects (Mohammed et al., 1993). Dampier et al. (1995) reported that the clearance of morphine in SCA patients was higher than typical values (Glare and Walsh, 1991). SCA patients have higher than normal levels of both unconjugated and conjugated bilirubin as a result of hemolysis as well as cholestasis (Embury et al., 1994). High circulating bilirubin levels may play a role in the modulation of enzyme activity. Maddrey et al. (1978) have reported an increase in the bilirubin-conjugating activity in SCA liver biopsy samples; bilirubin is known to be glucuronidated by human uridine glucuronosyltransferase (UGT) 1A1, as well as the corresponding rodent ugt1a1 (Iyanagi et al., 1998). Interestingly, a study by Sanchez and Tephly (1973) showed that exogenous bilirubin increased rat ugt activity in vivo as well as in microsomes from treated animals. Transgenic mouse models carrying the human sickle cell anemia gene have been developed in recent years. Sickle cell transgenic mice (SC) have a C57BL thalassemia background, and the human -globin gene and the human sickle -globin genes have been introduced into
2 DRUG METABOLISM IN SICKLE CELL TRANSGENIC MICE 99 TABLE 1 Human and rodent isozymes responsible for metabolism of various substrates Substrate Human Isozyme (Reference) Rodent Isozyme (Reference) Morphine UGT2B7(Coffman et al., 1997) ugt2b1*(coffman et al., 1996; King et al., 1997) Buprenorphine UGT1A1, 1A3, 2B7(Cheng et al., 1998) ugt1.1*, 2b1*(Coffman et al., 1996; King et al., 1997) Estradiol (E3G) UGT1A1(Senafi et al., 1994) ugt1a1 (?) Estradiol (E17G) UGT1A, 2B7(Senafi et al., 1994; Gall et al., 1999) ugt1a, 2b (?) Buprenorphine CYP3A4(Kobayashi et al., 1998) cyp3a (?) Codeine CYP2D6(Tyndale et al., 1997) cyp2d22**(blume et al., 2000) * Rat homolog. ** Mouse homolog. the mouse genome (Fabry et al., 1992). A more severe model of the disease is in the form of the sickle cell-knockout mice (SCKO); in addition to the introduction of the human genes, these mice are homozygous for the knockout of the murine -globin gene and heterozygous for the knockout of the murine -gene (Paszty et al., 1997). SCKO have a mixed genetic background. The transgenic mice have various pathological characteristics mirroring the human disease, such as extensive sickling of red blood cells on deoxygenation, retinopathy, and renal and hepatic pathology (Embury et al., 1994). The percentage of sickled erythrocytes that develop after complete deoxygenation in control mice (C57BL), SC, and SCKO is 0, 40, and 80%, respectively, and the percentage of nonalpha-globins that are comprised of the human S -globin is 0, 72, and 100%, respectively (R. P. Hebbel, unpublished data). These animal models provide an excellent opportunity to investigate alterations in drug disposition due to SCA. We hypothesize that enzyme induction could be one explanation for the higher observed clearance of opioid analgesics in SCA. To this end, in vitro hepatic metabolism by various rodent P450 and ugt isozymes was investigated in two different SCA mouse models. The substrates chosen were opioid analgesics commonly used in the management of SCA pain. Since buprenorphine is glucuronidated by various UGT1A and UGT2B isozymes, the glucuronidation of estradiol was also studied because estradiol is reported to be specifically glucuronidated at its 3-position by human UGT1A1 (Senafi et al., 1994). Table 1 shows the human and rodent isozymes responsible for the metabolism of the substrates used. For most of the substrates, mouse isozymes responsible for the reactions are unknown, and so the probable homologs based on human data are listed. For morphine and buprenorphine glucuronidation, the known rat isozymes are listed. Materials and Methods Morphine sulfate, morphine 3-glucuronide (M3G), buprenorphine hydrochloride, estradiol, estradiol 3-glucuronide (E3G), estradiol 17-glucuronide (E17G), ethynylestradiol (EE2), codeine sulfate, alamethicin, uridine diphosphoglucuronic acid (UDPGA), glucose 6-phosphate (G6P), G6P-dehydrogenase, -NADP, -glucuronidase, and phenytoin were obtained from Sigma- Aldrich (St. Louis, MO). Norbuprenorphine (NB) was obtained through the National Institute on Drug Abuse, from the Research Triangle Institute (Research Triangle Park, NC). All other chemicals used were reagent or HPLC grade. All transgenic mice were bred in the laboratory of Dr. R. P. Hebbel, University of Minnesota, and wild-type C57BL/6J mice were obtained from Harlan (Indianapolis, IN). All mice were maintained under specific pathogenfree conditions. Preparation of Mouse Liver Microsomes. Three groups of mice were used for the studies: control mice (wild-type C57BL/6J background), SC, and SCKO. For the preparation of microsomes, animals were sacrificed in a CO 2 chamber, and the livers were immediately harvested. Up to five livers were pooled and homogenized for each batch of microsomes. Microsomes were prepared by differential centrifugation, by a previously published method (Nelson et al., 2001). Briefly, liver homogenates were centrifuged at 9000g for 20 min at 4 C, and the resulting supernatant was centrifuged at 100,000g for 60 min at 4 C. The microsomal pellet was suspended in 0.1 M phosphate buffer containing 2 mm EDTA and 20% glycerol and stored at 80 C until further use. The protein content was determined using the BCA protein assay kit (Pierce Chemical, Rockford, IL). Microsomal Incubations for Rodent P450-Catalyzed Reactions. Incubation conditions were optimized for linearity with respect to protein and incubation period for each type of microsome and for every reaction. For the conversion of buprenorphine to NB as well as codeine to morphine, preliminary experiments showed that the reactions were linear up to 60 min and 1 mg/ml of protein. The necessary cofactors were added to the incubation mixture as two solutions: solution A contained -NADP, MgCl 2, and G6P in 50 mm Tris buffer (ph 7.4 at 37 C) and yielded final concentrations of 1 mm -NADP, 5 mm MgCl 2, and 5 mm G6P. Solution B was a G6P-dehydrogenase solution in 50 mm Tris buffer and gave a final concentration of 1.0 IU/ml of G6P-dehydrogenase in the incubation. The final volume of each incubation solution was made up to 250 l with 50 mm Tris buffer (ph 7.4 at 37 C). Mouse liver microsomes were at a final concentration of 1 mg/ml, and solutions A and B were preincubated at 37 C for 3 min. The reaction was started by the addition of varying concentrations of substrate and was terminated after 1 h by the addition of ice-cold acetonitrile (ACN) containing phenytoin as the internal standard. The solution was centrifuged to pellet the precipitated protein, and the supernatant was injected onto the HPLC column. Six replicates of each experiment were carried out with pooled mouse liver microsomes for each group. Microsomal Incubations for ugt-catalyzed Reactions. Incubation conditions were optimized for linearity with respect to protein and incubation period for each type of microsome and for every reaction. The conversion of morphine to M3G was linear up to 15 min, whereas the formations of buprenorphine glucuronide (BG), E3G, and E17G were linear up to 10 min. Alamethicin, a pore-forming peptide, was used to activate the microsomal preparations before incubation. Alamethicin concentration was optimized to achieve maximal activation of the microsomes. Thus, 75 M alamethicin was used for control and SCKO microsomes and 50 M alamethicin was used for SC microsomes. The final incubation volume in all cases was made up to 200 l using 0.1 M Tris buffer (ph 7.4 at 37 C). For the incubations, a mixture of 1 mg/ml of microsomal protein, alamethicin, 5 mm MgCl 2, and substrate was preincubated for 3 min at 37 C. The reaction was started by adding UDPGA to give a final concentration of 3 mm. Control incubations were performed without the addition of UDPGA. For morphine and buprenorphine, the reaction was terminated by the addition of ice-cold ACN containing phenytoin as the internal standard. For estradiol, the reaction was terminated with ice-cold ACN and subsequent addition of the internal standard, EE2. In all cases, the incubation solution was centrifuged at 13,000g for 2 min and the supernatant was used for HPLC analysis. Six replicates of each experiment were performed with pooled mouse liver microsomes for each group. For incubations for the conversion of buprenorphine to BG, preliminary incubations were carried out to verify the glucuronidation reaction; -glucuronidase was added to the reaction mixture, and the resulting disappearance of the BG peak with a corresponding increase of the buprenorphine peak confirmed that the metabolite peak was indeed BG. HPLC Analysis. The HPLC system used was a Beckman Gold 126 system (Beckman Coulter Inc., Fullerton, CA) with a 507e autosampler, a 166 UV detector, and a Gold Nouveau integration software (version 1.6, Beckman Coulter). Except for the formation of BG, metabolite formation was quantitated by comparing metabolite/internal standard peak area ratios in incubations
3 100 NAGAR ET AL. TABLE 2 Reversed-phase HPLC conditions for the analysis of the various CYP and UGT substrates Compound Mobile Phase Column Flow Rate (ml/min) Detection Retention Time (min) 1.0 UV 210 nm 26 Buprenorphine Phosphate buffer b and ACN (64:36 v/v) Reversed-phase Luna 5- m C18(2) 150 NB 4.6 mm; Phenomenex c 11 Phenytoin (I.S.) a 7 Codeine Phosphate buffer and ACN (70:30 v/v) Reversed-phase Luna 5- m C18(2) UV 210 nm 7 Morphine 4.6 mm; Phenomenex 4.6 Phenytoin (I.S.) 12.4 Morphine d Phosphate buffer and ACN (79:21 v/v) Reversed-phase Luna 5- m C18(2) UV 210 nm 16 M3G 4.6 mm; Phenomenex 6 Phenytoin (I.S.) 22 Buprenorphine Phosphate buffer and ACN (63:37 v/v) Reversed-phase Luna 5- m C18(2) UV 212 nm 9.4 BG 4.6 mm; Phenomenex 2.5 Phenytoin (I.S.) 3.5 Estradiol Acetate buffer e and ACN, gradient elution f Reversed-phase Supelco 5- m C UV 280 nm 24 E3G 4.6 mm; Supelco g 7 E17G 8.4 EE2 (I.S.) 25 a I.S., internal standard. b 10 mm phosphate buffer with 0.8 mm SDS, ph 2.1. c Phenomenex is based in Torrance, CA. d Lear et al., e 0.05 M ammonium acetate buffer, ph 4.5 (Ebner et al., 1993). f 26% ACN for 12 min, increase to 50% ACN over 1 min; 50% ACN for 7 min, increase to 85% ACN over 0.5 min; 85% ACN for 6 min, re-equilibration at 26% ACN. g Supelco is based in Bellefonte, PA. TABLE 3 Rodent P450-catalyzed reactions: Michaelis-Menten parameters for the formation of NB and morphine in control mouse, SC, and SCKO liver microsomes Metabolite (Isozyme) V max a (nmol/min mg) K m a ( M) V max /K m ( l/min mg) to a standard curve with known amounts of metabolite. Since a BG standard was unavailable, BG areas were quantitated against a buprenorphine standard curve and expressed as equivalent buprenorphine concentrations. UV spectra of both buprenorphine and BG by diode array detection in the 190- to 250-nm wavelength range showed an identical spectrum with a max at 212 nm. All assays were validated for inter- and intraday precision and accuracy, and the percentage of CV and bias were less than 10% throughout the concentration range studied (data not shown). The HPLC conditions for each substrate and its metabolites are shown in Table 2. Data Analysis. Metabolite formation data were fit to the simple form of the Michaelis-Menten equation (Gibaldi and Perrier, 1982): V V max S/ K m S where V is the initial rate of metabolite formation, V max is the maximum rate of metabolite formation, S is the substrate concentration, and K m is the Michaelis-Menten constant. Eadie-Hofstee plots were evaluated for linearity for each reaction. The nonlinear fit was carried out with KaleidaGraph 3.5 (Synergy Software, Reading, PA). Statistical comparisons for the Michaelis-Menten parameter estimates were carried out using a two-sided t test, assuming normal distribution of parameter estimates. A p value less than 0.01 was considered significant. Liver weights were compared for statistical significance with StatView 5.0 (SAS Institute Inc., Cary, NC). The ratio of V max to K m is the in vitro intrinsic clearance of the unbound drug. A theoretical in vivo intrinsic clearance of the unbound drug was calculated by multiplying the V max /K m value by the microsomal protein yield In Vivo Cl int ( l/min/g of body weight) NB (cyp3a) Control SC SCKO Morphine (cyp2d22) Control SC SCKO * a Data expressed as parameter estimate S.E. (n 6). * Value was significantly different than corresponding control values, as determined by a two-sided t test (p 0.01). for each type of liver. The microsomal protein yield was calculated from the liver weights, with a scaling factor of 45 mg/g of liver (Houston, 1994). Results The mean body weights of age-matched male control mice, SC, and SCKO were (mean S.D.), , and g, respectively, and the mean liver weights were , , and g, respectively. The mean body weight normalized liver weights (gram per gram of body weight) in control mice, SC, and SCKO were 0.074, 0.062, and 0.048, respectively. The microsomal protein yield was calculated using a scaling factor of 45 mg/g of liver (Houston, 1994). These values were 70.2, 92.7, and 72.5 mg for control mice, SC, and SCKO microsomes, respectively. The microsomal protein yield values were used to calculate theoretical in vivo Cl int values in Tables 3 and 4. Figure 1, a and b, shows the formation of NB from buprenorphine and morphine formation from codeine, with the corresponding Michaelis-Menten parameters of these rodent P450-catalyzed reactions reported in Table 3. All three groups showed similar NB formation kinetics. The formation of morphine from codeine showed a significantly higher V max in SCKO microsomes than in controls. The Eadie-Hofstee plots were linear for both NB and morphine formation (data not shown). Figure 2 shows the ugt-catalyzed formation curves for M3G (Fig.
4 DRUG METABOLISM IN SICKLE CELL TRANSGENIC MICE 101 TABLE 4 ugt-catalyzed reactions: Michaelis-Menten parameters for the formation of M3G, E3G, and E17G in control mouse, SC, and SCKO liver microsomes Metabolite (Isozyme) V max a (nmol/min mg) K m a ( M) V max /K m ( l/min mg) In Vivo Cl int (ml/min/g of body weight) M3G (ugt2b) Control SC * SCKO * E3G (ugt1a1) Control SC SCKO * E17G (ugt1a, 2b) Control SC * SCKO * a Data expressed as parameter estimate S.E. (n 6). * Values were significantly different than corresponding control values, as determined by a two-sided t test (p 0.01). FIG. 1.Rodent P450-catalyzed reactions: formation of NB (a) and morphine (b) in control mouse ( and irregularly dashed lines), SC (F and solid lines), and SCKO (Œ and evenly dashed lines) liver microsomes. Data are expressed as mean S.D. (n 6). Michaelis-Menten curves are representative curves drawn through mean data; parameter estimates were obtained by fitting the actual data. 2a), BG (Fig. 2b), E3G (Fig. 2c), and E17G (Fig. 2d), and the corresponding Michaelis-Menten parameter estimates are presented in Table 4. The V max of M3G formation was found to be significantly higher in SC and SCKO microsomes as compared with controls. The V max value in controls ( nmol/min mg) was close to other published values in the C57BL mouse liver microsomes (Bock et al., 1982; Hanioka et al., 1990). There was no significant difference in BG formation among the three groups, as seen in Fig. 2b. A simple Michaelis-Menten curve could not be fitted to the BG formation data, hence no parameter estimates are reported. The Eadie-Hofstee plot for BG formation was nonlinear and atypical in all groups of mice (Fig. 3), indicating the involvement of more than one ugt isozyme. For E3G formation, the V max in SCKO microsomes was significantly lower than in controls. The V max values for E17G formation were also significantly lower in SC and SCKO microsomes as compared with controls (Table 4). Discussion Pain in sickle cell anemia is commonly managed with opioid analgesics, but there are various clinical reports that pain is not alleviated in these patients even after intensive analgesic therapy (Beyer, 2000; Yaster et al., 2000). Our study explored the possibility of altered pharmacokinetics as a cause of higher dose requirements in SCA. Increased metabolism of drugs can lead to an increase in the overall clearance of drugs. Drugs such as morphine and codeine are classically thought of as high-clearance drugs, i.e., their overall clearance is affected only by hepatic blood flow and not by a change in the intrinsic clearance (Wilkinson and Shand, 1975). However, liver cirrhosis is common in SCA (Embury et al., 1994). It has been shown that in liver disease and cirrhosis, the liver can no longer be thought of as well stirred, and so the equations for drug clearance based on the well stirred model of the liver no longer hold true. Thus, hepatic enzyme activity becomes an important contributor to the overall clearance of even a high-clearance drug (Huet and Villeneuve, 1983). Interestingly, in a liver with cirrhosis, UGT function seems to remain unaltered, whereas human P450 function may be adversely affected (Patwardhan et al., 1981). Thus, it is important to consider how drug metabolism would change due to the pathophysiology of SCA compounded by liver cirrhosis. In a diseased liver in SCA, a normally high-extraction drug will probably be affected both by changes in hepatic blood flow and intrinsic clearance. Additionally, pathophysiological changes due to SCA such as increased circulating bilirubin levels may in fact increase human P450 and UGT activity, increasing the intrinsic clearance of various drugs. Higher free bilirubin concentrations in the liver could also competitively inhibit other UGT1A1 substrates. How the presence of sickle RBCs perturbs liver function is also an important consideration. The transgenic mouse models closely approximate the human disease, especially with phenotypic similarities such as enlarged liver, retinopathy, and renal pathology. A significant alteration in the metabolism of drugs by both rodent P450 and ugt isozymes in the transgenic mice was observed. Also, each isozyme shows a unique change in its drug-metabolizing capacity in these mouse models.
5 102 NAGAR ET AL. FIG. 2.ugt-Catalyzed reactions: formation of M3G (a), BG (b), E3G (c), and E17G (d) in control mouse ( and irregularly dashed lines), SC (F and solid lines), and SCKO (Œ and evenly dashed lines) liver microsomes. Data are expressed as mean S.D. (n 6). Michaelis-Menten curves are representative curves drawn through mean data; parameter estimates were obtained by fitting the actual data. Specifically, our results indicate the following: 1) the mouse cyp3a isozyme responsible for the formation of NB from buprenorphine shows no change in activity among the three groups; 2) the mouse cyp2d22 isozyme responsible for the conversion of codeine to morphine is induced in SCKO microsomes, showing a significantly higher V max than in control microsomes; 3) the mouse ugt2b isozyme responsible for morphine glucuronidation is induced in both SC and SCKO microsomes and shows a significantly higher V max than controls; and 4) the mouse ugt1a isozyme responsible for estradiol glucuronidation shows decreased V max values for E3G formation in SC microsomes and decreased V max values for E3G and E17G formation in SCKO microsomes. The V max /K m ratios in either case, however, are not very different from control values. In all cases, the observed significant differences were more pronounced in the SCKO, a more severe model of SCA. The increased conversion of codeine to morphine does not support the hypothesis that the decreased analgesic effect in SCA is due to enhanced metabolism, since morphine is a potent analgesic. However, the sequential conversion of morphine to the inactive M3G is also increased, and the relative rates of the two reactions in vivo would determine the overall analgesic effect. It is of interest to note that in preliminary studies, there were significant differences in baseline response to tail-flick tests among the control mice, SC, and SCKO, indicating differences in nociceptive response (Nagar, 2003). All the rodent P450- and ugt-catalyzed reactions studied except BG formation gave linear Eadie-Hofstee plots (data not shown), indicative of single-enzyme kinetics in the substrate concentration range studied. BG formation showed atypical kinetics (Figs. 1b and 3) with nonlinear Eadie-Hofstee plots. This may be due to the involvement of more than one ugt isozyme. Atypical Eadie-Hofstee curves such as hook-shaped plots are usually obtained due to allosteric sites, multiple isozymes, or activation kinetics (Fisher et al., 2000; Kenworthy et al., 2001; Oda and Kharasch, 2001). The V max /K m ratio is the maximum in vitro Cl int value for a given substrate. A theoretical in vivo Cl int value was calculated from mean values of V max and K m with the use of the microsomal protein yield as a scaling factor (Houston, 1994). The average liver weight of SC was significantly higher than controls, leading to a higher value of microsomal protein yield. Differences in the theoretical in vivo Cl int values followed the same trend as those in the corresponding V max /K m ratios (Tables 3 and 4). Liver enlargement is also very common in SCA patients (Embury et al., 1994). Thus, if human P450 and UGT levels were induced in SCA, a significant increase in the intrinsic clearance of a drug per gram of liver tissue would translate to an even greater increase in the total hepatic intrinsic clearance per liver weight. The mechanisms for differential alterations in enzyme activity in SCA need to be determined. SCA patients are known to have increased levels of both unconjugated and conjugated bilirubin as a result of hemolysis and biliary obstruction (Schubert, 1986). Sickle cell transgenic mice are hyperbilirubinemic, with higher conjugated and unconjugated serum bilirubin levels than control mice (Nagar, 2003). An increase in rat ugt activity has been reported after bilirubin treatment both in vitro and in vivo (Sanchez and Tephly, 1973; Munoz et al., 1987; Li et al., 2000). Bilirubin has been implicated in the aryl
6 DRUG METABOLISM IN SICKLE CELL TRANSGENIC MICE 103 FIG. 3.Eadie-Hofstee plots for the formation of BG in control mice (a), SC (b), and SCKO (c) microsomes. Data expressed as mean values, n 6. hydrocarbon receptor-mediated induction of rodent cyp1a1 (Sinal and Bend, 1997; Phelan et al., 1998). In addition, it appears that increased bilirubin levels in mice activate the nuclear hormone receptor, constitutive androstane receptor, resulting in an increase in bilirubin clearance (Huang et al., 2003). On the other hand, recent studies of human UGT1A1 activity have shown that UGT1A1-catalyzed reactions like E3G formation can be slightly inhibited by bilirubin, which acts as a competitive inhibitor (Williams et al., 2002). These reports support the hypothesis that high bilirubin levels may play an important role in the activation and inhibition of various human P450 and UGT isozymes in SCA. The effect of bilirubin on morphine disposition is currently being studied in mouse and rat models. In addition to altered pharmacokinetics, the pharmacodynamics of analgesics also need to be evaluated in SCA. It is also important to note that morphine is converted only to M3G in rodents, whereas in humans it is also glucuronidated at the 6-position, with the resulting morphine 6-glucuronide being much more potent than even the parent compound as an analgesic (Christrup, 1997). How the increased glucuronidation of morphine would thus affect the analgesic activity of morphine in human SCA patients needs to be investigated. However, previous clinical reports indicate that patients require significantly larger doses of morphine for adequate pain control. In conclusion, there is a marked alteration in the in vitro microsomal enzyme kinetics of various ugt and rodent P450 isozymes in the sickle cell transgenic mouse models studied. There is evidence for the induction of the rodent P450 isozyme responsible for converting codeine to morphine and the ugt isozyme responsible for glucuronidating morphine. Further studies in human patients are needed to validate the animal models as well as to clarify the role of altered pharmacokinetics and pharmacodynamics in sickle cell anemia pain. Acknowledgments. We thank Dr. Marie Applie at the Department of Biostatistics, University of Minnesota, for statistical consultation. We also acknowledge the National Institute of Drug Abuse, Research Triangle Institute, for the gift of norbuprenorphine. References Beyer JE (2000) Judging the effectiveness of analgesia for children and adolescents during vaso-occlusive events of sickle cell disease. J Pain Symptom Manage 19: Blume N, Leonard J, Xu ZJ, Watanabe O, Remotti H, and Fishman J (2000) Characterization of Cyp2d22, a novel cytochrome P450 expressed in mouse mammary cells. Arch Biochem Biophys 381: Bock KW, Lilienblum W, and Pfeil H (1982) Functional heterogeneity of UDPglucuronosyltransferase activities in C57BL/6 and DBA/2 mice. Biochem Pharmacol 31: Cheng Z, Rios GR, King CD, Coffman BL, Green MD, Mojarrabi B, Mackenzie PI, and Tephly TR (1998) Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7. Toxicol Sci 45: Christrup LL (1997) Morphine metabolites. Acta Anaesthesiol Scand 41: Coffman BL, Rios GR, and Tephly TR (1996) Purification and properties of two rat liver phenobarbital-inducible UDP-glucuronosyltransferases that catalyze the glucuronidation of opioids. Drug Metab Dispos 24: Coffman BL, Rios GR, King CD, and Tephly TR (1997) Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 25:1 4. Dampier CD, Setty BNY, Logan J, Ioli JG, and Dean R (1995) Intravenous morphine pharmacokinetics in pediatric patients with sickle cell disease. J Pediatr 126: Ebner T, Remmel RP, and Burchell B (1993) Human bilirubin UDP-glucuronosyltransferase catalyzes the glucuronidation of ethinylestradiol. Mol Pharmacol 43: Embury SH, Hebbel RP, Mohandas N, and Steinberg MH (1994) Sickle Cell Disease: Basic Principles and Clinical Practice, Raven Press, New York. Fabry ME, Nagel RL, Pachnis A, Suzuka SM, and Constantini F (1992) Higher expression of human s - and -globins in transgenic mice: hemoglobin composition and hematological consequences. Proc Natl Acad Sci USA 89: Fisher MB, Campanale K, Ackerman BL, Vandenbranden M, and Wrighton SA (2000) In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 28: Gall WE, Zawada G, Mojarrabi B, Tephly TR, Green MD, Coffman BL, Mackenzie PI, and Radominska-Pandya A (1999) Differential glucuronidation of bile acids, androgens and estrogens by human UGT1A3 and 2B7. J Steroid Biochem Mol Biol 70: Gibaldi M and Perrier D (1982) Pharmacokinetics, 2nd ed, pp , Marcel Dekker, Inc, New York. Glare PA and Walsh TD (1991) Clinical pharmacokinetics of morphine. Ther Drug Monit 13:1 23. Hanioka N, Hoshikawa Y, Mitsui T, Oguri K, and Yoshimura H (1990) Species difference in codeine diphosphate-glucuronyltransferase activity of liver microsomes. J Pharmacobio-Dyn 13: Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47: Huang W, Zhang J, Chua SS, Qatanani M, Han Y, Granata R, and Moore DD (2003) Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proc Natl Acad Sci USA 100: Huet P-M and Villeneuve J-P (1983) Determinants of drug disposition in patients with cirrhosis. Hepatology 3: Iyanagi T, Emi Y, and Ikushiro S (1998) Biochemical and molecular aspects of genetic disorders of bilirubin metabolism. Biochim Biophys Acta 1407: Kenworthy KE, Clarke SE, Andrews J, and Houston JB (2001) Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab Dispos 29: King CD, Rios GR, Green MD, MacKenzie PI, and Tephly TR (1997) Comparison of stably expressed rat UGT1.1 and UGT2B1 in the glucuronidation of opioid compounds. Drug Metab Dispos 25: Kobayashi K, Yamamoto T, Chiba K, Tani M, Shimada N, Ishizaki T, and Kuroiwa Y (1998)
7 104 NAGAR ET AL. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos 26: Lear L, Nation RL, and Stupans I (1991) Influence of morphine concentration on detergent activation of rat liver morphine-udp-glucuronosyltransferase. Biochem Pharmacol 42 (Suppl):S55 S60. Li YQ, Prentice DA, Howard ML, Mashford ML, and Desmond PV (2000) Bilirubin and bile acids may modulate their own metabolism via regulating uridine diphosphateglucuronosyltransferase expression in the rat. J Gastroenterol Hepatol 15: Maddrey WC, Cukier JO, Maglalang AC, Boitnott JK, and Odell GB (1978) Hepatic bilirubin UDP-glucuronyltransferase in patients with sickle cell anemia. Gastroenterology 74: Mohammed SS, Ayass M, Mehta P, Kedar A, Gross S, and Derendorf H (1993) Codeine disposition in sickle cell patients compared with healthy volunteers. J Clin Pharmacol 33: Munoz ME, Esteller A, and Gonzalez J (1987) Substrate induction of bilirubin conjugation and biliary excretion in the rat. Clin Sci (Lond) 73: Nagar SV (2003) Metabolism of Opioid Analgesics in Sickle Cell Transgenic Mice. Ph.D. thesis, University of Minnesota, Minneapolis, MN. Nelson MH, Birnbaum AK, and Remmel RP (2001) Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors. Epilepsy Res 44: Oda Y and Kharasch ED (2001) Metabolism of levo- -acetylmethadol (LAAM) by human liver cytochrome P450: involvement of CYP3A4 characterized by atypical kinetics with two binding sites. J Pharmacol Exp Ther 297: Paszty C, Brion CM, Manci E, Witkowska HE, Stevens ME, Mohandas N, and Rubin EM (1997) Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science (Wash DC) 278: Patwardhan RV, Johnson RF, Hoyumpa A Jr, Sheehan JJ, Desmond PV, Wilkinson GR, Branch RA, and Schenker S (1981) Normal metabolism of morphine in cirrhosis. Gastroenterology 81: Pauling L, Itano H, Singer SJ, and Wells IC (1949) Sickle cell anemia: a molecular disease. Science (Wash DC) 110: Phelan D, Winter GM, Rogers WJ, Lam JC, and Denison MS (1998) Activation of the Ah receptor signal transduction pathway by bilirubin and biliverdin. Arch Biochem Biophys 357: Sanchez E and Tephly TR (1973) Activation of hepatic microsomal glucuronyl transferase by bilirubin. Life Sci 13: Schubert TT (1986) Hepatobiliary system in sickle cell disease. Gastroenterology 90: Senafi SB, Clarke DJ, and Burchell B (1994) Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. Biochem J 303: Sinal CJ and Bend JR (1997) Aryl hydrocarbon receptor-dependent induction of Cyp1a1 by bilirubin in mouse hepatoma Hepa 1c1c7 cells. Mol Pharmacol 52: Steinberg MH (1999) Drug therapy: management of sickle cell disease. N Engl J Med 340: Tyndale RF, Droll KP, and Sellers EM (1997) Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics 7: Wilkinson GR and Shand DG (1975) A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18: Williams JA, Ring BJ, Cantrell VE, Campanale K, Jones DR, Hall SD, and Wrighton SA (2002) Differential modulation of human UGT1A1 activity. Drug Metab Rev 34 (Suppl 1):196. Yaster M, Kost-Byerly S, and Maxwell LG (2000) The management of pain in sickle cell disease. Pediatr Clin N Am 47:
In vitro assay of six UGT isoforms in human liver microsomes, using cocktails of probe substrates and LC-MS/MS
Supplemental data for Drug Metabolism and Disposition In vitro assay of six UGT isoforms in human liver microsomes, using cocktails of probe substrates and LC-MS/MS Kyung-Ah Seo, Hyo-Ji Kim, Eun Sook Jeong,
More informationReceived December 14, 2009; accepted March 19, 2010
0090-9556/10/3807-1211 1217$20.00 DRUG METABOLISM AND DISPOSITION Vol. 38, No. 7 Copyright 2010 by The American Society for Pharmacology and Experimental Therapeutics 31625/3591857 DMD 38:1211 1217, 2010
More informationXTreme 200 Human Liver Microsomes Lot No Human Liver Microsomes Pool of 200 (100 Male and 100 Female) Suspension medium: 250 mm sucrose
XTreme 200 Human Liver Microsomes Lot No. 1710084 Human Liver Microsomes Pool of 200 (100 Male and 100 Female) Suspension medium: 250 mm sucrose H2610 0.5 ml at 20 mg/ml H2620 1.0 ml at 20 mg/ml H2630
More informationMetabolism of 1 - and 4-Hydroxymidazolam by Glucuronide Conjugation Is Largely Mediated by UDP-Glucuronosyltransferases 1A4, 2B4, and 2B7
0090-9556/10/3811-2007 2013$20.00 DRUG METABOLISM AND DISPOSITION Vol. 38, No. 11 Copyright 2010 by The American Society for Pharmacology and Experimental Therapeutics 35295/3635725 DMD 38:2007 2013, 2010
More informationThe metabolism of 1 - and 4-hydroxymidazolam by glucuronide conjugation is. largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7
DMD Fast This article Forward. has not Published been copyedited on and August formatted. 16, The 2010 final version as doi:10.1124/dmd.110.035295 may differ from this version. The metabolism of 1 - and
More informationTHE EFFECT OF INCUBATION CONDITIONS ON THE ENZYME KINETICS OF UDP-GLUCURONOSYLTRANSFERASES
0090-9556/03/3106-762 767$7.00 DRUG METABOLISM AND DISPOSITION Vol. 31, No. 6 Copyright 2003 by The American Society for Pharmacology and Experimental Therapeutics 1031/1067920 DMD 31:762 767, 2003 Printed
More informationAndrew Rowland, Kathleen M. Knights, Peter I. Mackenzie, and John O. Miners
0090-9556/08/3606-1056 1062$20.00 DRUG METABOLISM AND DISPOSITION Vol. 36, No. 6 Copyright 2008 by The American Society for Pharmacology and Experimental Therapeutics 21105/3344446 DMD 36:1056 1062, 2008
More informationJ. ANDREW WILLIAMS, 1 BARBARA J. RING, VARON E. CANTRELL, KRISTINA CAMPANALE, DAVID R. JONES, STEPHEN D. HALL, AND STEVEN A.
0090-9556/02/3011-1266 1273$7.00 DRUG METABOLISM AND DISPOSITION Vol. 30, No. 11 Copyright 2002 by The American Society for Pharmacology and Experimental Therapeutics 818/1021294 DMD 30:1266 1273, 2002
More informationEVALUATION OF 5-HYDROXYTRYPTOPHOL AND OTHER ENDOGENOUS SEROTONIN (5-HYDROXYTRYPTAMINE) ANALOGS AS SUBSTRATES FOR UDP- GLUCURONOSYLTRANSFERASE 1A6
0090-9556/04/3208-862 869$20.00 DRUG METABOLISM AND DISPOSITION Vol. 32, No. 8 Copyright 2004 by The American Society for Pharmacology and Experimental Therapeutics 1391/1163921 DMD 32:862 869, 2004 Printed
More informationChapter 4. Drug Biotransformation
Chapter 4 Drug Biotransformation Drug Biotransformation 1 Why is drug biotransformation necessary 2 The role of biotransformation in drug disposition 3 Where do drug biotransformation occur 4 The enzymes
More informationIN VITRO GLUCURONIDATION USING HUMAN LIVER MICROSOMES AND THE PORE-FORMING PEPTIDE ALAMETHICIN
0090-9556/00/2805-0560 566$03.00/0 DRUG METABOLISM AND DISPOSITION Vol. 28, No. 5 Copyright 2000 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. DMD 28:560 566,
More informationK. Bowalgaha, D. J. Elliot, P. I. Mackenzie, K. M. Knights, and J. O. Miners
0090-9556/07/3503-363 370$20.00 DRUG METABOLISM AND DISPOSITION Vol. 35, No. 3 Copyright 2007 by The American Society for Pharmacology and Experimental Therapeutics 13052/3178465 DMD 35:363 370, 2007 Printed
More informationISSN: ; CODEN ECJHAO E-Journal of Chemistry 2011, 8(3),
ISSN: 0973-4945; CODEN ECJHAO E- Chemistry http://www.e-journals.net 2011, 8(3), 1275-1279 Simultaneous Determination of Paracetamol, Phenylephrine Hydrochloride, Oxolamine Citrate and Chlorpheniramine
More informationPelagia Research Library
Available online at www.pelagiaresearchlibrary.com Der Pharmacia Sinica, 2015, 6(1):6-10 ISSN: 0976-8688 CODEN (USA): PSHIBD Validated RP-HPLC method for simultaneous estimation of metformin hydrochloride
More informationShort Communication Bilirubin Glucuronidation Revisited: Proper Assay Conditions to Estimate Enzyme Kinetics with Recombinant UGT1A1
0090-9556/10/3811-1907 1911$20.00 DRUG METABOLISM AND DISPOSITION Vol. 38, No. 11 Copyright 2010 by The American Society for Pharmacology and Experimental Therapeutics 33829/3630350 DMD 38:1907 1911, 2010
More informationScreening by immunoassay and confirmation & quantitation by GC-MS of buprenorphine and norbuprenorphine in urine, whole blood and serum
Screening by immunoassay and confirmation & quantitation by GC-MS of buprenorphine and norbuprenorphine in urine, whole blood and serum NINA KANGAS, SIRPA MYKKÄNEN, SANNA KYLLÖNEN, PÄIVI RAJALA, KARI ARINIEMI
More informationDefinition of bilirubin Bilirubin metabolism
Definition of bilirubin Bilirubin metabolism obilirubin formation otransport of bilirubin in plasma ohepatic bilirubin transport oexcretion through intestine Other substances conjugated by glucuronyl transferase.
More informationPilot experiments to investigate the glucuronidation of axitinib with human liver microsomes.
Zientek MA, Goosen TC, Tseng E, Lin J, Bauman JN, Walker GS, Kang P, Jiang Y, Freiwald S, Neul D and Smith BJ. In Vitro Kinetic Characterization of Axitinib Metabolism. Drug Metab Dispos. Supplemental
More informationIdentification of Human UGT2B7 as the Major Isoform Involved in the O-Glucuronidation of Chloramphenicol
0090-9556/10/3803-368 375$20.00 DRUG METABOLISM AND DISPOSITION Vol. 38, No. 3 Copyright 2010 by The American Society for Pharmacology and Experimental Therapeutics 29900/3567562 DMD 38:368 375, 2010 Printed
More informationSorafenib (free base, >99%) was obtained from Chemie Tek (Indianapolis, IN), and
Supplemental Methods Chemicals and Reagents Sorafenib (free base, >99%) was obtained from Chemie Tek (Indianapolis, IN), and isotopically-labeled 13 C- 2 H 3 -sorafenib (labeled atoms on N-methyl position)
More informationIn vitro metabolism of montelukast by Cytochrome P450s (CYPs) and UDPglucuronosyltransferases
In vitro metabolism of montelukast by Cytochrome P450s (CYPs) and UDPglucuronosyltransferases (UGTs) Josiane de Oliveira Cardoso, Regina Vincenzi Oliveira, Jessica Bo Li Lu Zeruesenay Desta Department
More informationThe influence of bile acids homeostasis by cryptotanshinone-containing herbs
The influence of bile acids homeostasis by cryptotanshinone-containing herbs Chengcheng Gao, Tianheng Ma, Liqun Pang, Rui Xie* Department of Gastroenterology, Huai an First People s Hospital, Nanjing Medical
More informationDISPOSITION OF FLAVONOIDS VIA RECYCLING: COMPARISON OF INTESTINAL VERSUS HEPATIC DISPOSITION
0090-9556/05/3312-1777 1784$20.00 DRUG METABOLISM AND DISPOSITION Vol. 33, No. 12 Copyright 2005 by The American Society for Pharmacology and Experimental Therapeutics 3673/3061802 DMD 33:1777 1784, 2005
More informationMEDCHEM 570. First Midterm. January 30, 2015
Name MEDCHEM 570 First Midterm January 30, 2015 Instructions: Exam packet totals 7 pages. The last page has a 5 points extra credit question. If you need additional space for a question go to the back
More informationBiosynthesis of imipramine glucuronide and characterization of imipramine glucuronidation catalyzed by recombinant UGT1A4 1
Acta Pharmacologica Sinica 2006 May; 27 (5): 623 628 Full-length article Biosynthesis of imipramine glucuronide and characterization of imipramine glucuronidation catalyzed by recombinant UGT1A4 1 Ming-rong
More informationHPTLC Determination of Atomoxetine Hydrochloride from its Bulk Drug and Pharmaceutical Preparations
Asian Journal of Chemistry Vol. 20, No. 7 (2008), 5409-5413 HPTLC Determination of Atomoxetine Hydrochloride from its Bulk Drug and Pharmaceutical Preparations S.S. KAMAT, VINAYAK T. VELE, VISHAL C. CHOUDHARI
More informationNew RP - HPLC Method for the Determination of Valproic acid in Human Plasma
New RP - HPLC Method for the Determination of Valproic acid in Human Plasma C.Venkata Nagendra Prasad 1, Ch.Santhosh Kumari a, B.Srinivasa Reddy 1 and Prof. J. Sriramulu 2 1 Sree Dattha Institute of Pharmacy,
More informationSUPPLEMENTARY MATERIAL
SUPPLEMENTARY MATERIAL Purification and biochemical properties of SDS-stable low molecular weight alkaline serine protease from Citrullus Colocynthis Muhammad Bashir Khan, 1,3 Hidayatullah khan, 2 Muhammad
More informationNIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2011 April 6.
NIH Public Access Author Manuscript Published in final edited form as: Transplant Proc. 1991 December ; 23(6): 2777 2779. Pharmacokinetics of Cyclosporine and Nephrotoxicity in Orthotopic Liver Transplant
More informationPharmacogenetics of Codeine. Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA
Pharmacogenetics of Codeine Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA 1 Codeine Overview Naturally occurring opium alkaloid Demethylated to morphine for analgesic effect
More informationBasic Concepts of TDM
TDM Lecture 1 5 th stage What is TDM? Basic Concepts of TDM Therapeutic drug monitoring (TDM) is a branch of clinical pharmacology that specializes in the measurement of medication concentrations in blood.
More informationCHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW
132 CHAPTER 6 DEVELOPMENT AND VALIDATION OF A STABILITY-INDICATING RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION OF PARACETAMOL, TRAMADOL HYDROCHLORIDE AND DOMPERIDONE IN A COMBINED DOSAGE FORM 6.1 INTRODUCTION
More informationIt the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues.
It the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues. Primarily depends on: 1.Regional blood flow. 2.Capillary permeability. 3.Protein
More informationThe importance of pharmacogenetics in the treatment of epilepsy
The importance of pharmacogenetics in the treatment of epilepsy Öner Süzer and Esat Eşkazan İstanbul University, Cerrahpaşa Faculty of Medicine, Department of Pharmacology and Clinical Pharmacology Introduction
More informationVariability Due to Genetic Differences
1 Variability Due to Genetic Differences Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland 2 Objectives Understand how between individual variation may contribute to :» drug
More informationAnkit et al Journal of Drug Delivery & Therapeutics; 2013, 3(2), Available online at RESEARCH ARTICLE
Ankit et al Journal of Drug Delivery & Therapeutics; 2013, 3(2), 26-30 26 Available online at http://jddtonline.info RESEARCH ARTICLE METHOD DEVELOPMENT AND ITS VALIDATION FOR QUANTITATIVE SIMULTANEOUS
More informationSupporting Information for:
Supporting Information for: Methylerythritol Cyclodiphosphate (MEcPP) in Deoxyxylulose Phosphate Pathway: Synthesis from an Epoxide and Mechanisms Youli Xiao, a Rodney L. Nyland II, b Caren L. Freel Meyers
More informationAnalysis of Isoflavones with the PerkinElmer Flexar FX-15 UHPLC System Equipped with a PDA Detector
application Note UHPLC Author Njies Pedjie PerkinElmer, Inc. Shelton, CT 06484 USA Analysis of Isoflavones with the PerkinElmer Flexar FX-15 UHPLC System Equipped with a PDA Detector Introduction Foods
More informationIJPAR Vol.3 Issue 4 Oct-Dec-2014 Journal Home page:
IJPAR Vol.3 Issue 4 Oct-Dec-2014 Journal Home page: ISSN: 2320-2831 Research article Open Access Method development and validation of tenofovir disoproxil fumerate and emtricitabine in combined tablet
More informationKit for assay of thioredoxin
FkTRX-02-V2 Kit for assay of thioredoxin The thioredoxin system is the major protein disulfide reductase in cells and comprises thioredoxin, thioredoxin reductase and NADPH (1). Thioredoxin systems are
More information10 mm KCl in a Ti-15 zonal rotor at 35,000 rpm for 16 hr at
Proc. Nat. Acad. SCi. USA Vol. 68, No. 11, pp. 2752-2756, November 1971 Translation of Exogenous Messenger RNA for Hemoglobin on Reticulocyte and Liver Ribosomes (initiation factors/9s RNA/liver factors/reticulocyte
More informationGlutathione S-Transferase Assay Kit
Glutathione S-Transferase Assay Kit Catalog Number KA1316 96 assays Version: 05 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Background... 3 Principle of the Assay...
More informationBioequivalence Studies of Two Formulations of Famciclovir Tablets by HPLC Method
Asian Journal of Chemistry Vol. 19, No. 6 (2007), 4245-4250 Bioequivalence Studies of Two Formulations of Famciclovir Tablets by HPLC Method K.V. SUBRAHMANYAM*, P. MOHANRAJ, P. SANDHYARANI, V.S. SARAVANAN
More informationPharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne
Pharmacokinetics for Physicians Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne The Important Therapeutic Questions What drug? What dose? How long? Drug Dosage
More informationNIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2010 September 22.
NIH Public Access Author Manuscript Published in final edited form as: Transplant Proc. 1990 February ; 22(1): 57 59. Effect of Hepatic Dysfunction and T Tube Clamping on FK 506 Pharmacokinetics and Trough
More informationN-Glucuronidation of Carbamazepine in Human Tissues Is Mediated by UGT2B7
0022-3565/04/3113-1131 1137$20.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 311, No. 3 Copyright 2004 by The American Society for Pharmacology and Experimental Therapeutics 73114/1178720
More informationDevelopment and Validation for Simultaneous Estimation of Sitagliptin and Metformin in Pharmaceutical Dosage Form using RP-HPLC Method
International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.5, No.4, pp 1736-1744, Oct-Dec 2013 Development and Validation for Simultaneous Estimation of Sitagliptin and Metformin
More informationPrerequisites Protein purification techniques and protein analytical methods. Basic enzyme kinetics.
Case 19 Purification of Rat Kidney Sphingosine Kinase Focus concept The purification and kinetic analysis of an enzyme that produces a product important in cell survival is the focus of this study. Prerequisites
More informationDetermination of Tetracyclines in Chicken by Solid-Phase Extraction and High-Performance Liquid Chromatography
Determination of Tetracyclines in Chicken by Solid-Phase Extraction and High-Performance Liquid Chromatography Application ote Food Safety Authors Chen-Hao Zhai and Yun Zou Agilent Technologies Co. Ltd.
More informationObjectives Making CYP450, Drug Interactions, & Pharmacogenetics Easy
Objectives Making, Drug Interactions, & Pharmacogenetics Easy Anthony J. Busti, MD, PharmD, FNLA, FAHA Describe the differences between phase I and phase II metabolic pathways. Identify the most common
More informationToshifumi Shiraga, Kanako Yajima, Kenta Suzuki, Katsuhiro Suzuki, Tadashi Hashimoto, Takafumi Iwatsubo, Aiji Miyashita, and Takashi Usui
1521-009X/12/4002-276 282$25.00 DRUG METABOLISM AND DISPOSITION Vol. 40, No. 2 Copyright 2012 by The American Society for Pharmacology and Experimental Therapeutics 42614/3741564 DMD 40:276 282, 2012 Identification
More informationMetabolism. Objectives. Metabolism. 26 July Chapter 28 1
Metabolism bjectives Describe various processes by which drugs are metabolized Describe induction and inhibition of metabolism Use the venous equilibration model to describe hepatic clearance and the effect
More informationAnalytical Method Development and Validation for the Estimation of Guaifenesin and Dextromethorphan by RP-HPLC
Human Journals Research Article September 2018 Vol.:13, Issue:2 All rights are reserved by Ramya Sree Borra et al. Analytical Method Development and Validation for the Estimation of Guaifenesin and Dextromethorphan
More informationHyderabad, India. Department of Pharmaceutical Chemistry, Glocal University, Saharanpur, India.
International Journal On Engineering Technology and Sciences IJETS RP-HPLC Method development and validation for the Simultaneous Estimation of Metformin and Empagliflozine in Tablet Dosage Form Shaik
More information6/6/2018. Nalbuphine: Analgesic with a Niche. Mellar P Davis MD FCCP FAAHPM. Summary of Advantages. Summary of Advantages
Nalbuphine: Analgesic with a Niche Mellar P Davis MD FCCP FAAHPM 1 Summary of Advantages Safe in renal failure- fecal excretion Analgesia equal to morphine with fewer side effects Reduced constipation
More informationREVERSE PHASE HPLC METHOD FOR THE ANALYSIS OF ALFUZOSIN HYDROCHLORIDE IN PHARMACEUTICAL DOSAGE FORMS
Int. J. Chem. Sci.: 6(1), 2008, 399-404 REVERSE PHASE HPLC METHOD FOR THE ANALYSIS OF ALFUZOSIN HYDROCHLORIDE IN PHARMACEUTICAL DOSAGE FORMS S. APPALA RAJU, ARVIND B. KARADI and SHOBHA MANJUNATH HKES s
More informationSimultaneous estimation of Metformin HCl and Sitagliptin in drug substance and drug products by RP-HPLC method
International Journal of Chemical and Pharmaceutical Sciences 2017, Mar., Vol. 8 (1) ISSN: 0976-9390 IJCPS Simultaneous estimation of Metformin HCl and Sitagliptin in drug substance and drug products by
More informationStability indicating RP-HPLC method development and validation of Etizolam and Propranolol hydrochloride in pharmaceutical dosage form
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original
More informationJohn O. Miners, Kushari Bowalgaha, David J. Elliot, Pawel Baranczewski, and Kathleen M. Knights
0090-9556/11/3904-644 652$20.00 DRUG METABOLISM AND DISPOSITION Vol. 39, No. 4 Copyright 2011 by The American Society for Pharmacology and Experimental Therapeutics 37036/3677337 DMD 39:644 652, 2011 Printed
More informationA HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC ASSAY FOR LERCANIDIPINE HYDROCHLORIDE
Int. J. Chem. Sci.: 6(1), 2008, 441-446 A HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC ASSAY FOR LERCANIDIPINE HYDROCHLORIDE S. APPALA RAJU, ARVIND B. KARADI and SHOBHA MANJUNATH HKES s College of Pharmacy,
More informationMechanism of Action of N-Acetylcysteine in the Protection Against the Hepatotoxicity of Acetaminophen in Rats In Vivo
Mechanism of Action of N-Acetylcysteine in the Protection Against the Hepatotoxicity of Acetaminophen in Rats In Vivo BERNHARD H. LAUTERBURG, GEORGE B. CORCORAN, and JERRY R. MITCHELL, Baylor College of
More informationBETA-GLUCURONIDASE PRODUCT LINE INNOVATION THROUGH CHEMISTRY. FORENSICS
FORENSICS BETA-GLUCURONIDASE PROD LINE INNOVATION THROUGH CHEMISTRY ABALONASE Purified Beta-Glucuronidase Formula Clean, Rapid And Reliable Shown from left to right: Abalonase purified Beta-glucuronidase
More informationReceived May 30, 2007; accepted August 15, 2007
0090-9556/07/3511-1990 1995$20.00 DRUG METABOLISM AND DISPOSITION Vol. 35, No. 11 Copyright 2007 by The American Society for Pharmacology and Experimental Therapeutics 16816/3267964 DMD 35:1990 1995, 2007
More informationAvailable online at Scholars Research Library
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2015, 7 (3):157-161 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationValproate Case 1: Pharmacokinetics Jose de Leon, MD
Valproate Case 1: Pharmacokinetics 2-12-16 Jose de Leon, MD 1. Valproate Case 1 J Clin Psychopharmacology 2009;29:509-11 http://www.ncbi.nlm.nih.gov/pubmed/19745660 Educational Objectives At the conclusion
More informationApplication Note. Agilent Application Solution Analysis of ascorbic acid, citric acid and benzoic acid in orange juice. Author. Abstract.
Agilent Application Solution Analysis of ascorbic acid, citric acid and benzoic acid in orange juice Application Note Author Food Syed Salman Lateef Agilent Technologies, Inc. Bangalore, India 8 6 4 2
More informationJournal of Chemical and Pharmaceutical Research
Available on line www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 0975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 2011, 3(2):770-775 Validation of Rapid Liquid Chromatographic
More informationCase 19 Purification of Rat Kidney Sphingosine Kinase
Case 19 Purification of Rat Kidney Sphingosine Kinase Focus concept The purification and kinetic analysis of an enzyme that produces a product important in cell survival is the focus of this study. Prerequisites
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen This full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/14779
More informationDEVELOPMENT AND VALIDATION OF NEW HPLC METHOD FOR THE ESTIMATION OF PALIPERIDONE IN PHARMACEUTICAL DOSAGE FORMS
ISSN: 0974-1496 e-issn: 0976-0083 CODEN: RJCABP http://www.rasayanjournal.com http://www.rasayanjournal.co.in DEVELOPMENT AND VALIDATION OF NEW HPLC METHOD FOR THE ESTIMATION OF PALIPERIDONE IN PHARMACEUTICAL
More informationExploiting BDDCS and the Role of Transporters
Exploiting BDDCS and the Role of Transporters (Therapeutic benefit of scientific knowledge of biological transporters, understanding the clinical relevant effects of active transport on oral drug absorption)
More informationPHA5128 Dose Optimization II Case Study I Spring 2013
Silsamicin is an investigational compound being evaluated for its antimicrobial effect. The route of administration for this drug is via intravenous bolus. Approximately 99.9% of this drug is eliminated
More information[GANN, 59, ; October, 1968] CHANGES IN ALDOLASE ISOZYME PATTERNS OF HUMAN CANCEROUS TISSUES
[GANN, 59, 415-419; October, 1968] UDC 616-006-092.18 CHANGES IN ALDOLASE ISOZYME PATTERNS OF HUMAN CANCEROUS TISSUES Kiyoshi TSUNEMATSU, Shin-ichi YOKOTA, and Tadao SHIRAISHI (Third Department of Internal
More informationMETHOD DEVELOPMENT AND VALIDATION BY RP-HPLC FOR ESTIMATION OF ZOLPIDEM TARTARATE
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Ramalakshmi et al. SJIF Impact Factor 6.647 Volume 7, Issue 2, 1010-1018 Research Article ISSN 2278 4357 METHOD DEVELOPMENT AND VALIDATION BY RP-HPLC
More informationA Validated Chiral Liquid Chromatographic Method for The Enantiomeric Separation of Dapoxetine Hydrochloride
Received on 15/05/2012; Revised on 22/05/2012; Accepted on 09/06/2012 A Validated Chiral Liquid Chromatographic thod for The Enantiomeric Separation of Dapoxetine Hydrochloride T.Rohith 1 and S. Ananda
More informationA Simple and Accurate Method for the Rapid Quantitation of Drugs of Abuse in Urine Using Liquid Chromatography
Application Note LCMS-109 A Simple and Accurate Method for the Rapid Quantitation of Drugs of Abuse in Urine Using Liquid Chromatography Time of Flight (LC-TOF) Mass Spectrometry Introduction Many clinical
More informationReverse Phase HPLC Analysis of Atomoxetine in Pharmaceutical Dosage Forms
Asian Journal of Chemistry Vol. 21, No. 2 (2009), 829-833 Reverse Phase HPLC Analysis of Atomoxetine in Pharmaceutical Dosage Forms B.V.V.S. JAGADEESH, S. SATYANARAYANA RAJU, V.JAYATHIRTHA RAO and J.V.L.N.
More informationAvailable online Research Article
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2016, 8(1):171-176 Research Article ISSN : 0975-7384 CODEN(USA) : JCPRC5 Reverse phase high performance liquid chromatography
More informationPelagia Research Library
Available online at www.pelagiaresearchlibrary.com Der Pharmacia Sinica, 2014, 5(5):91-98 ISSN: 0976-8688 CODEN (USA): PSHIBD A novel RP-HPLC method development and validation of Perindopril Erbumine in
More informationIn Vitro Glucuronidation of Thyroxine and Triiodothyronine by Liver Microsomes and Recombinant Human UDP-Glucuronosyltransferases
0090-9556/07/3512-2203 2210$20.00 DRUG METABOLISM AND DISPOSITION Vol. 35, No. 12 Copyright 2007 by The American Society for Pharmacology and Experimental Therapeutics 16972/3277631 DMD 35:2203 2210, 2007
More informationF. Al-Rimawi* Faculty of Science and Technology, Al-Quds University, P.O. Box 20002, East Jerusalem. Abstract
JJC Jordan Journal of Chemistry Vol. 4 No.4, 2009, pp. 357-365 Development and Validation of Analytical Method for Fluconazole and Fluconazole Related Compounds (A, B, and C) in Capsule Formulations by
More informationDEVELOPMENT OF RP-HPLC METHOD FOR ESTIMATION OF DROTAVERINE HYDROCHLORIDE IN PHARMACEUTICAL FORMULATIONS
Int. J. Chem. Sci.: 6(4), 2008, 2055-2061 DEVELOPMENT OF RP-HPLC METHOD FOR ESTIMATION OF DROTAVERINE HYDROCHLORIDE IN PHARMACEUTICAL FORMULATIONS B. S. SASTRY a, S. GANANADHAMU and G. DEVALA RAO K. V.
More informationSupplemental material to this article can be found at:
Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2013/01/03/dmd.112.049072.dc1 1521-009X/41/3/582 591$25.00 http://dx.doi.org/10.1124/dmd.112.049072 DRUG
More informationInvolvement of CYP2C8 and UGT1A9 in the metabolism of a novel gastroprokinetic agent, Z-338
Involvement of CYP2C8 and UGT1A9 in the metabolism of a novel gastroprokinetic agent, Z-338 S. Furuta 1, E. Kamada 1, T. Sugimoto 1, Y. Kawabata 1, X. C. Wu 2, J. Skibbe 3, E. Usuki 3, A. Parkinson 3 and
More informationEdgar Naegele. Abstract
Simultaneous determination of metabolic stability and identification of buspirone metabolites using multiple column fast LC/TOF mass spectrometry Application ote Edgar aegele Abstract A recent trend in
More informationDesigner Fentanyls Drugs that kill and how to detect them. Cyclopropylfentanyl
Designer Fentanyls Drugs that kill and how to detect them Cyclopropylfentanyl Science for a safer world The in vitro metabolism of cyclopropylfentanyl Simon Hudson & Charlotte Cutler, Sport and Specialised
More informationRobust extraction, separation, and quantitation of structural isomer steroids from human plasma by SPE-UHPLC-MS/MS
TECHNICAL NOTE 21882 Robust extraction, separation, and quantitation of structural isomer steroids human plasma by SPE-UHPLC-MS/MS Authors Jon Bardsley 1, Kean Woodmansey 1, and Stacy Tremintin 2 1 Thermo
More informationDMD Fast Forward. Published on October 26, 2011 as DOI: /dmd
DMD Fast This Forward. article has not Published been copyedited on and October formatted. 26, The 2011 final version as doi:10.1124/dmd.111.042614 may differ from this version. Identification of UDP-glucuronosyltransferases
More informationMethod Validation for Simultaneous Estimation of Prednisolone and Abiraterone Acetate by RP-HPLC
Journal of Chronotherapy and Drug Delivery ORIGINAL RESEARCH PAPER Method Validation for Simultaneous Estimation of Prednisolone and Abiraterone Acetate by RP-HPLC Divyashree S*, Veena MK, Channabasavaraj
More informationClick to edit Master title style
A Short Course in Pharmacokinetics Chris Town Research Pharmacokinetics Outline Pharmacokinetics - Definition Ideal Pharmacokinetic Parameters of a New Drug How do we optimize PK for new compounds Why
More informationWorld Journal of Pharmaceutical Research
World Journal of Pharmaceutical ReseaRch Volume 3, Issue 3, 4527-4535. Research Article ISSN 2277 715 DEVELOPMENT AND VALIDATION OF STABILITY INDICATING HPLC METHOD FOR ESTIMATION OF RAMOSETRON Zarana
More informationALVIMOPAN 0.0 OVERVIEW
ALVIMOPAN 0.0 OVERVIEW A. Alvimopan is a peripherally restricted mu-opioid receptor antagonist. B. DOSING INFORMATION : For the treatment of opioid bowel dysfunction, oral alvimopan doses between 0.5 milligrams
More informationTRANSPORT OF AMINO ACIDS IN INTACT 3T3 AND SV3T3 CELLS. Binding Activity for Leucine in Membrane Preparations of Ehrlich Ascites Tumor Cells
Journal of Supramolecular Structure 4:441 (401)-447 (407) (1976) TRANSPORT OF AMINO ACIDS IN INTACT 3T3 AND SV3T3 CELLS. Binding Activity for Leucine in Membrane Preparations of Ehrlich Ascites Tumor Cells
More informationBiopharmaceutics Drug Disposition Classification System (BDDCS) --- Its Impact and Application
Biopharmaceutics Drug Disposition Classification System (BDDCS) --- Its Impact and Application Leslie Z. Benet, Ph.D. Professor of Bioengineering and Therapeutic Sciences Schools of Pharmacy and Medicine
More informationRelative Quantitation of Human Polymorphonuclear Leukocyte Cell Membrane GPEtn Lipids
Relative Quantitation of Human Polymorphonuclear Leukocyte Cell Membrane GPEtn Lipids Using the QTRAP System with mtraq Reagents Karin A. Zemski-Berry 1, John M. Hevko 2, and Robert C. Murphy 1 1 Department
More informationConstitutive Regulation of P450s by Endocrine Factors
References: Constitutive Regulation of P450s by Endocrine Factors Meyer UA. Endo-xenobiotic crosstalk and the regulation of cytochromes P450. Drug Metab Rev 39:639-46, 2007. Waxman DJ and O Connor C. Growth
More informationProbe substrate and enzyme source-dependent inhibition of UDPglucuronosyltransferase
Probe substrate and enzyme source-dependent inhibition of UDPglucuronosyltransferase (UGT) 1A9 by wogonin Chengcheng Gao, Rui Xie, Tianheng Ma, Wei Yan, Liqun Pang* Department of Gastroenterology, Huai
More informationGlutathione Peroxidase Assay Kit
Glutathione Peroxidase Assay Kit Catalog Number KA0882 100 assays Version: 04 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Background... 3 General Information... 4
More informationWhen choosing an antiepileptic ... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs. Based on a presentation by Barry E.
... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs Based on a presentation by Barry E. Gidal, PharmD Presentation Summary A physician s choice of an antiepileptic drug (AED) usually depends
More information